Artículos científicos sobre vacunas contra el COVID19
-
December 2020 update: Information from the American College of Rheumatology Regarding Vaccination Against SARS-CoV-2
Background: As of 12/21/20, two vaccines have been granted emergency use authorization (EUA) from the US Food and Drug Administration (FDA) to prevent COVID-19 caused by SARS-CoV-2. There are at least 18 vaccines in Phase 3 testing worldwide with over 200 additional vaccine candidates in development. The science is briskly evolving, and the latest developments can be accessed at www.cdc.gov. This document will discuss vaccine development, clinical questions, and patient education...Descargar artículo.
-
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Abstract: Background: Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age...Descargar artículo.
-
Guide to infection control in the hospital: The 2019 Coronavirus Disease (COVID-19) Vaccines
Abstract: COVID-19 disease, caused by the SARS-CoV-2 virus, emerged in Wuhan, China in December 2019 and due to its very rapid global spread, it has been declared a Public Health Emergency of International Concern (PHEIC). Like other coronaviruses, SARS-CoV-1 and MERS-CoV, COVID-19 has attracted major global public health attention due to its novelty, high infectivity, pathogenicity, and lack of effective therapeutic or preventive interventions. Despite all global public health efforts including the implementation of aggressive nonpharmaceutical interventions (NPIs), the novel coronavirus has been able to spread globally causing over 96 million cases and leading to over 2 million deaths in 223 countries, areas, or territories as of mid-January 2021...Descargar artículo.
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Abstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently...Descargar artículo.
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
We recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARSCoV-2; those interim results covered a period of 57 days after the first vaccination.1,2 Here, we describe immunogenicity data 119 days after the first vaccination (90 days after the second vaccination) in 34 healthy adult participants in the same trial who received two injections of vaccine at a dose of 100 μg. The injections were received 28 days apart. The recipients were stratified according to age (18 to 55 years, 56 to 70 years, or ≥71 years), and the assays used have been described previously...Descargar artículo.
-
The COVID-19 Vaccine Communication Handbook: A practical guide for improving vaccine communication and ghting misinformation
This handbook is for journalists, doctors, nurses, policy makers, researchers, teachers, students, parents – in short, it’s for everyone who wants to know more: about the COVID-19 vaccines, how to talk to others about them, how to challenge misinformation about the vaccines...Descargar artículo.
-
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Abstract: Background: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19...Descargar artículo.
-
Prospects for a safe COVID-19 vaccine
Abstract: Rapid development of an efficacious vaccine against the viral pathogen SARS-CoV-2, the cause of the coronavirus disease-2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease...Descargar artículo.
-
COVID-19: A review of therapeutic strategies and vaccine candidates
Abstract: The world is engulfed by one of the most widespread and significant public health crises in decades as COVID-19 has become among the leading causes of death internationally. The novel SARS-CoV-2 coronavirus which causes COVID-19 has unified the scientific community in search of therapeutic and preventative solutions...Descargar artículo.
-
An Uncertain Public — Encouraging Acceptance of Covid-19 Vaccines
The potential for vaccines to interrupt U.S. transmission of Covid-19 depends not only on technical efficiency in vaccine distribution, but also on the willingness of a large proportion of the public to be vaccinated. Though there has been strong demand for the relatively small amount of vaccine available initially, maintaining interest in vaccination is...Descargar artículo.
-
Choices in a Crisis — Individual Preferences among SARS-CoV-2 Vaccines
The extraordinarily swift development of effective vaccines against SARS-CoV-2 offers new optimism about combating the Covid-19 pandemic. So far, vaccine demand far exceeds supply, and people generally cannot choose which vaccine they receive. In the United States, this lack of choice has generated little debate given the similar mechanism of action, number of required doses, safety profile, and efficacy of the two vaccines approved in December 2020...Descargar artículo.
-
The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies
Abstract: There is an urgent need for effective countermeasures against the current emergence and accelerating expansion of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Induction of herd immunity by mass vaccination has been a very successful strategy for preventing the spread of many infectious diseases, hence protecting the most vulnerable population groups unable to develop immunity, for example individuals with immunodeficiencies or a weakened immune system due to underlying medical or debilitating conditions...Descargar artículo.
-
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
Abstract: Baden et al.1 report on a phase 3 clinical trial of the mRNA-1273 vaccine against SARS-CoV-2, and they provide information on immediate injection-site reactions, which were observed in 84.2% of the participants after the first dose. The trial also showed that delayed injection-site reactions (defined in that trial as those with an onset on or after day 8)...Descargar artículo.